Pfizer Receives FDA Approval for Elranatamab in Relapsed or Refractory Multiple Myeloma

Pfizer today announced that the FDA has granted accelerated approval to Elrexfio (elranatamab-bcmm) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Elrexfio is a bispecific antibody that targets both BCMA on myeloma cells and CD3 on T cells, directing the immune system to kill cancer cells. In the MagnetisMM-3 trial, Elrexfio demonstrated an overall response rate of 61% in heavily pretreated patients. This approval provides a new treatment option for patients with limited therapeutic alternatives.